Medical Therapy. Efficacy or Lack of Efficacy

Inhaled Nitric Oxide Treatment of Early Pulmonary Hypertension to Reduce the Risk of Death or Bronchopulmonary Dysplasia in Infants Born Extremely Preterm: A Masked Randomized Controlled Trial

Hussnain Mirza, Jorge Garcia, Matthew Zussman, Rajan Wadhawan, Julie Pepe, William OhAdvent Health for Children.United States Journal of PediatricsJ Pediatr 2024; DOI: 10.1016/j.jpeds.2024.114427 AbstractObjective: To determine whether inhaled nitric oxide (iNO) treatment of early pulmonary hypertension (PH) would decrease the risk of death or bronchopulmonary dysplasia (BPD) among infants born extremely preterm.Study design: This was a single-center, masked, […]

Inhaled Nitric Oxide Treatment of Early Pulmonary Hypertension to Reduce the Risk of Death or Bronchopulmonary Dysplasia in Infants Born Extremely Preterm: A Masked Randomized Controlled Trial Read More »

Treprostinil Use in the NICU

Diana LeeUniversity of Pennsylvania School of Nursing.United States Advances in Neonatal CareAdv Neonat Care 2024; 24: 554-560DOI: 10.1097/ANC.0000000000001218 AbstractBackground: Treprostinil is a prostacyclin analogue that is frequently used in the pediatric and adult population to treat pulmonary hypertension; however, it is not often a drug of choice for patients in the neonatal intensive care unit (NICU).Purpose: To evaluate

Treprostinil Use in the NICU Read More »

CDK6-mediated endothelial cell cycle acceleration drives arteriovenous malformations in hereditary hemorrhagic telangiectasia

Sajeth Dinakaran, Sima Qutaina, Haitian Zhao, Yuefeng Tang, Zhimin Wang, Santiago Ruiz, Aya Nomura-Kitabayashi, Christine N. Metz, Helen M. Arthur, Stryder M. Meadows, Lionel Blanc, Marie E. Faughnan, Philippe MarambaudFeinstein Institutes for Medical Research and Northwell Health. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Institut Pasteur de Montevideo. Newcastle University. Tulane University. Cohen

CDK6-mediated endothelial cell cycle acceleration drives arteriovenous malformations in hereditary hemorrhagic telangiectasia Read More »

Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial

Aditya Kallimath, Sujata Deshpande, Pari Singh, Reema Garegrat, Satyan Lakshminrusimha, Rajesh Maheshwari, Pradeep SuryawanshiBharati Vidyapeeth (Deemed to be University) Medical College. Imperial College. University of California Davis Children’s Hospital. Westmead Hospital.India, United Kingdom, United States and Australia BioMedical Central PediatricsBMC Pediatr 2024; 24: DOI: 10.1186/s12887-024-05107-0 AbstractBackground: Access to inhaled nitric oxide (iNO) is limited in low resource

Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial Read More »

Oxygen saturation targets in neonatal care: A narrative review

Tri C. Nguyen, Rajeshwari Madappa, Heather M. Siefkes, Michelle J. Lim, Kanya Mysore Siddegowda, Satyan LakshminrusimhaKaiser Permanente North California. SIGMA Hospital. University of California Davis Children’s Hospital.United States Early Human DevelopmentEarly Hum Dev 2024; 199:DOI: 10.1016/j.earlhumdev.2024.106134 AbstractOptimal oxygenation requires the delivery of oxygen to meet tissue metabolic demands while minimizing hypoxic pulmonary vasoconstriction and oxygen toxicity.

Oxygen saturation targets in neonatal care: A narrative review Read More »

Current Pharmaceutical Strategies in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN): A Comprehensive Review of Therapeutic Agents

Divyanshi Kaplish, Jayant D. Vagha, Sachin Rathod, Aditya JainJawaharlal Nehru Medical College and Datta Meghe Institute of Higher Education and Research.India CureusCureus 2024; 16: DOI: 10.7759/cureus.70307 AbstractPersistent Pulmonary Hypertension of the Newborn (PPHN) is a life-threatening condition characterized by the failure of normal circulatory transition after birth, leading to sustained pulmonary hypertension and severe hypoxemia. Despite

Current Pharmaceutical Strategies in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN): A Comprehensive Review of Therapeutic Agents Read More »

Sildenafil as Bridge Therapy for Inhaled Nitric Oxide in Preterm Neonates

Harris Khawaja, Timothy A. Sanders, Michael Schreiber, Deborah Bondi, Pooja Shah, Gillian BrennanUniversity of Chicago Medicine and Comer Children’s Hospital.United States Journal of Pediatric Pharmacology and TherapeuticsJ Pediatr Pharmacol Ther 2024; 25: 525-529DOI: 10.5863/1551-6776-29.5.525 AbstractObjective: Inhaled nitric oxide (iNO) is a mainstay of treatment for infants with persistent pulmonary hypertension. However, abrupt discontinuation of inhaled nitric oxide

Sildenafil as Bridge Therapy for Inhaled Nitric Oxide in Preterm Neonates Read More »

Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants

Karan R. Kumar, Elizabeth C. Ciociola, Kayla R. Skinner, Gargi M. Dixit, Sunshine Alvarez, Elijah K. Benjamin, Jeffrey C. Faulkner, Rachel G. Greenberg, Reese H. Clark, Daniel K. Benjamin Jr, Christoph P. Hornik, Jan Hau LeeDuke University School of Medicine. University of North Carolina School of Medicine. Pediatrix Center for Research. KK Women’s and Children’s

Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants Read More »

Massive pulmonary thromboembolism in an adolescent with SARS-CoV-2 infection

Verónica Chauriye Kuncar, Cecilia Castillo Acevedo, Carlos Acuña Aguirre, Piaignacia Díaz EspejoHospital Luis Calvo Mackenna.Chile Archivos Argentinos De PediatriaArch Argent Pediatr 2024; DOI: 10.5546/aap.2024-10474.eng AbstractThromboembolic events incidence is low in pediatrics; high suspicion and explicit management algorithms are essential. We present a 12-year-old female patient with two weeks of dyspnea, orthopnea, and ankle edema. Tests showed

Massive pulmonary thromboembolism in an adolescent with SARS-CoV-2 infection Read More »

Nintedanib preserves lung growth and prevents pulmonary hypertension in a hyperoxia-induced lung injury model

Kathy L. Ding, Caroline Smith, Gregory Seedorf, Steven H. AbmanUniversity of Colorado School of Medicine.United States Pediatric ResearchPediatr Res 2024; DOI: 10.1038/s41390-024-03562-0 AbstractBackground: Bronchopulmonary dysplasia (BPD), the chronic lung disease associated with prematurity, is characterized by poor alveolar and vascular growth, interstitial fibrosis, and pulmonary hypertension (PH). Although multifactorial in origin, the pathophysiology of BPD is partly

Nintedanib preserves lung growth and prevents pulmonary hypertension in a hyperoxia-induced lung injury model Read More »

Scroll to Top